TJPC(SH:600488)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 990,540,207.94, representing an increase of 11.33% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 67,479,421.90, a significant increase of 199.30% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 65,625,537.56, up 214.97% year-on-year[4]. - Basic earnings per share were CNY 0.062, reflecting a growth of 195.24% year-on-year[4]. - Net profit for Q1 2023 was ¥86,684,786.16, significantly up from ¥20,198,171.72 in Q1 2022, marking a growth of 329.5%[15]. - The net profit attributable to the parent company for Q1 2023 was ¥67,479,421.90, compared to ¥22,545,650.89 in Q1 2022, representing a significant increase[16]. - The total comprehensive income for Q1 2023 was ¥87,413,663.40, up from ¥21,422,002.25 in Q1 2022[16]. - The basic and diluted earnings per share for Q1 2023 were both ¥0.062, compared to ¥0.021 in Q1 2022, indicating a substantial improvement[16]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 182,559,986.10, an increase of 157.12% compared to the previous year[4]. - Cash inflows from operating activities for Q1 2023 totaled ¥854,021,932.28, compared to ¥676,987,593.44 in Q1 2022, reflecting a growth of approximately 26.1%[20]. - The net cash flow from operating activities for Q1 2023 was ¥182,559,986.10, significantly higher than ¥71,001,771.81 in Q1 2022[20]. - Cash and cash equivalents at the end of Q1 2023 amounted to ¥634,376,254.46, compared to ¥238,026,479.93 at the end of Q1 2022, showing a strong increase[21]. - The company incurred a net cash outflow from investing activities of ¥27,561,016.64 in Q1 2023, compared to a larger outflow of ¥54,822,833.34 in Q1 2022[21]. - The net cash outflow from financing activities for Q1 2023 was ¥127,834,883.84, contrasting with a net inflow of ¥13,204,190.02 in Q1 2022[21]. - The company received cash from borrowings amounting to ¥56,000,000.00 in Q1 2023, down from ¥80,404,449.66 in Q1 2022[21]. - The company reported a decrease in other cash received related to financing activities, totaling ¥0.00 in Q1 2023, compared to ¥105,000,000.00 in Q1 2022[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,621,276,388.42, a decrease of 0.44% from the end of the previous year[4]. - The total assets of the company as of March 31, 2023, were ¥6,621,276,388.42, a slight decrease from ¥6,650,699,943.31 at the end of 2022[13]. - Total liabilities decreased to ¥2,778,280,934.91 in Q1 2023 from ¥2,896,862,345.04 in Q4 2022, a reduction of 4.1%[13]. - The equity attributable to shareholders increased to CNY 3,042,515,751.08, up 2.36% from the end of the previous year[4]. - The company's total equity as of March 31, 2023, was ¥3,842,995,453.51, compared to ¥3,753,837,598.27 at the end of 2022, indicating an increase of 2.4%[13]. Research and Development - The subsidiary Tianjin Jinyao Pharmaceutical Co., Ltd. received approval for clinical trials of a new inhalation powder for COPD, indicating ongoing R&D efforts[9]. - The company’s product Furosemide Injection is expected to be selected in the eighth batch of national drug centralized procurement, which could enhance market share and brand influence[10]. - Research and development expenses increased to ¥46,733,026.35 in Q1 2023, up from ¥33,062,281.74 in Q1 2022, reflecting a growth of 41.5%[15]. Regulatory and Compliance Issues - The company faced administrative penalties totaling CNY 27,721,311.36 and CNY 29,884,312.48 for its subsidiaries, which will impact the 2022 profits[10].